文献速递免疫规划传染病防控与疫情报告

V114十五价肺炎球菌结合疫苗在50岁及以上成人中的3期安全性与免疫原性试验

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
PubMed 文献 · Vaccine · 2021-09-08

这项3期试验将1202名≥50岁成人随机分配接种单剂V114或PCV13,评估安全性、耐受性和免疫原性。V114对13个共有血清型达到非劣效,对2个独有血清型(22F、33F)达到优效,对血清型3也达到优效。常见不良事件为注射部位疼痛、疲劳和肌痛。

要点

  • V114对13个共有血清型的OPA GMT比值达到非劣效(2倍界值)。
  • V114对独有血清型22F和33F的OPA GMT比值达到优效(2倍界值)。
  • V114对血清型3的OPA GMT比值达到优效(1.2倍界值)。

核心结论

  • V114在≥50岁成人中对13个共有血清型非劣效于PCV13,对22F和33F优效,对血清型3优效。

研究设计与样本

  • 3期随机对照试验,1202名≥50岁成人按1:1随机接种单剂V114(N=602)或PCV13(N=600),按年龄分层。

主要发现

  • 两组最常见不良事件为注射部位疼痛、疲劳和肌痛。
  • V114对13个共有血清型的OPA GMT比值(V114/PCV13)第30天满足2倍非劣效界值。
  • V114对22F和33F的OPA GMT比值满足2倍优效界值,且≥4倍升高的参与者比例差值满足0.10优效界值。
  • V114对血清型3的OPA GMT比值满足1.2倍优效界值,≥4倍升高的比例差值满足0优效界值。

关键数值与推荐

  • 非劣效界值:第30天OPA GMT比值(V114/PCV13)的2倍界值,针对13个共有血清型。
  • 优效界值:第30天OPA GMT比值(V114/PCV13)的2倍界值及≥4倍升高比例差值的0.10界值,针对22F和33F。
  • 优效界值:OPA GMT比值(V114/PCV13)的1.2倍界值及≥4倍升高比例差值的0界值,针对血清型3。

临床怎么用

  • 为≥50岁成人接种V114可覆盖PCV13的13个血清型并额外覆盖22F和33F。
  • V114对血清型3的免疫应答优于PCV13,可用于该血清型相关疾病防控。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal conjugate vaccines (PCVs) have greatly reduced the incidence of pneumococcal disease, yet unmet medical need remains due to increased disease caused by non-vaccine serotypes (STs). V114 (VAXNEUVANCETM, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA) is a 15-valent PCV containing 13 serotypes in licensed PCV13 and 2 additional serotypes (22F, 33F) which significantly contribute to pneumococcal disease burden. This phase 3 trial compared safety, tolerability, and immunogenicity of V114 to PCV13 in adults ≥50 years of age. METHODS: Adults were randomized 1:1 to receive a single dose of V114 or PCV13; randomization was stratified by age (50-64 years, 65-74 years, and ≥75 years). Adverse events (AEs) were collected following vaccination. Serotype-specific opsonophagocytic activity (OPA) and immunoglobulin G (IgG) antibodies were measured prior to and 30 days after vaccination (Day 30). Primary objectives included assessing noninferiority of V114 to PCV13 for the 13 shared serotypes and superiority of V114 to PCV13 for the two unique serotypes. Superiority of V114 to PCV13 for shared serotype 3 was assessed as a secondary objective. RESULTS: Overall, 1,202 participants were vaccinated (V114 N = 602, PCV13 N = 600). The most commonly reported AEs across both groups were injection-site pain, fatigue, and myalgia. V114 met noninferiority criteria compared to PCV13 for the 13 shared serotypes (using a 2-fold non-inferiority margin for the ratio of OPA geometric mean titers [GMTs] [V114/PCV13] at Day 30) and met superiority for the 2 unique serotypes (using a 2-fold super-superiority margin for the ratio of OPA GMTs [V114/PCV13] at Day 30 and a 0.10 super-superiority margin for the difference in proportions of participants with ≥4-fold rise from prevaccination to Day 30). V114 met superiority criteria compared to PCV13 for serotype 3 (based on a super-superiority margin of 1.2 for the ratio of the OPA GMTs [V114/PCV13] and a superiority margin of 0 for the difference in proportions of participants with ≥4-fold rise). [NCT03950622, EudraCT#2018-004316-22, Japic-CTI#194845].

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Platt HL, Cardona JF, Haranaka M, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2021. PMID: 34507861. doi:10.1016/j.vaccine.2021.08.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。